Piramal Pharma Ltd (PPL) has released its FY2025 Sustainability Report under the theme Innovating Responsibly. Growing Sustainably., showcasing a year of measurable progress across environmental, social, and governance pillars. The report outlines the company’s decarbonization glidepath, operational milestones, and stakeholder-centric initiatives, reinforcing its commitment to long-term value creation through science-led innovation and ethical business practices.
Key Highlights From The FY2025 Report
• Achieved a 6 percent year-on-year reduction in Scope 1 and Scope 2 greenhouse gas emissions
• Increased renewable energy usage by 7.8 percent, with 20.2 percent of total energy sourced from bioenergy
• Attained zero hazardous waste to landfill and set a target to recycle 90 percent of non-hazardous waste
• Saved 2.10 lakh kilolitres of freshwater through integrated water stewardship programs
• Converted coal-fired steam boilers at the Digwal facility to renewable biomass briquettes
Responsible Operations And Climate Action
• PPL’s decarbonization strategy includes transitioning to energy-efficient technologies and expanding renewable energy adoption across sites
• Biodiversity initiatives involved planting over 2,000 saplings and maintaining 30 percent green cover at Indian facilities
• Waste segregation and circularity programs were scaled to reduce landfill dependency and promote reuse
• The company’s water conservation efforts focused on rainwater harvesting, recycling, and process optimization
Business Resilience And Governance
• PPL maintained 100 percent compliance with its Code of Conduct training across global operations
• The Board composition included 50 percent independent directors and 30 percent women representation, exceeding statutory norms
• Conducted structured risk assessments and policy development to embed ethical practices and enhance transparency
• Assessed 26.5 percent of critical suppliers on sustainability criteria, with capacity-building plans for 30 percent by FY2026
Quality, Excellence, And Regulatory Performance
• Completed 36 successful regulatory inspections, including two by the USFDA
• Executed 165 customer audits globally, reinforcing trust and compliance across markets
• Continued digital transformation through Catalyst NxGen (S/4HANA), deploying 17 governance dashboards for operational agility
• Achieved customer satisfaction scores of 85 percent in CDMO/PPS and 87 percent in Critical Care/PCC segments
Stakeholder Centricity And Social Impact
• Community development programs focused on education, skill-building, and health initiatives at manufacturing sites
• Human capital management included safety training, diversity programs, and employee engagement platforms
• PPL’s sustainability strategy aligns with multiple United Nations Sustainable Development Goals, ensuring global relevance
• The company’s efforts were externally assured by DNV, adding credibility to its disclosures and performance metrics
Reporting Framework And Assurance
• The FY2025 report was prepared in accordance with the Global Reporting Initiative Universal Standards 2021
• It incorporates all nine disclosure requirements under GRI 1, GRI 2, and GRI 3, ensuring comprehensive coverage of material topics
• The report includes a GHG verification statement and assurance declaration, reinforcing data integrity and transparency
Conclusion
Piramal Pharma’s FY2025 Sustainability Report reflects a deepened commitment to responsible growth, operational excellence, and stakeholder engagement. With clear targets for decarbonization, waste reduction, and ethical governance, the company is positioning itself as a global leader in sustainable pharmaceutical practices. As it continues to embed ESG principles across its value chain, PPL’s journey offers a blueprint for resilience and innovation in a rapidly evolving industry.
Sources: Piramal Pharma FY2025 Sustainability Report, Futunn Newswire, Piramal Pharma Sustainability Portal.
